Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial to Assess Ongoing Pregnancy Rate With OXO-001 (200/300 mg) or Placebo at 10 Weeks Following Fresh Single Blastocyst Transfer From Donor Oocyte IVF/ICSI

NCT05076032 is registered in ClinicalTrials.gov with OXOLIFE as lead sponsor.

NCT NCT05076032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05076032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial to Assess Ongoing Pregnancy Rate With OXO-001 (200/300 mg) or Placebo at 10 Weeks Following Fresh Single Blastocyst Transfer From Donor Oocyte IVF/ICSI
Lead sponsor
OXOLIFE
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2021
Completion date
December 1, 2023
Enrollment
408 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

infertility, infertility, female